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Abstract: Chronic constipation is a common condition that significantly impacts health care 
utilization, productivity, and quality of life. Laxatives are commonly used, although often 
insufficient in restoring normal bowel function or providing adequate relief. There remains a 
significant need for the development of novel agents to optimize treatment of this condition. 
This review provides an overview of the preclinical and clinical trial data, supporting the 
efficacy and safety of prucalopride, a highly selective 5-HT
4
 receptor agonist that has been 
approved by the European Medicine Agency for the treatment of chronic constipation in adults 
who have failed standard laxative therapy. Unlike older 5-HT
4
 agonists, prucalopride has not 
been associated with adverse cardiovascular side effects or QT prolongation owing to its high 
selectivity and affinity for the 5-HT
4
 receptor without clinically significant cross-reactivity at 
the human ether-à-go-go-related gene (hERG) potassium channel or 5-HT receptor subtypes 
that have previously been implicated in adverse cardiovascular events and arrhythmias. Care-
ful safety assessments have documented the relative safety and tolerability of this agent in 
various patient groups. Focus has also been placed on demonstrating efficacy with regard to 
bowel function, symptoms, and patient-reported outcomes such as the Patient Assessment of 
Constipation-Symptoms and the Patient Assessment of Constipation Quality of Life scores to 
support the use of prucalopride as a safe and effective therapeutic option for the management 
of chronic constipation.
Keywords: prucalopride, chronic constipation, 5-HT
4
 agonist, safety, prokinetic, PAC-QOL
Definition, epidemiology, and impact of constipation
Constipation is a common condition defined by bowel symptoms that may include 
infrequent or difficult passage of stool, hardness of stool, or a sensation of incom-
plete evacuation.1 The consensus-based Rome IV criteria incorporate many of these 
symptoms, defining constipation as two or more of the following symptoms in at least 
25% of defecations: straining, lumpy or hard stools, sensation of incomplete evacu-
ation, sensation of anorectal blockage, manual maneuvers to facilitate defecations, 
or fewer than three defecations per week. Criteria should be fulfilled for at least the 
last 3 months with symptom onset at least 6 months prior to diagnosis.2 The Rome 
criteria include patients with “functional constipation;” however, this term has been 
avoided in the last two American Gastroenterological Association technical reviews 
on constipation in consideration of the fact that there exists a subset of patients with 
slow-transit constipation that is not considered to be truly “functional”.1
In North America, the reported prevalence of constipation ranges from 2% to 27%, 
although most estimates report rates ranging from 12% to 19%.3 A prior systematic 
review investigating epidemiology of constipation reported worldwide prevalence 
rates ranging from 0.7% to 79% with an overall median of 16% and a median of 
Correspondence: Andrea Shin
Department of Medicine, Division of 
Gastroenterology and Hepatology, 
indiana University School of Medicine, 
702 Rotary Circle Suite 225, 
indianapolis, iN 46202, USA
Tel +1 317 274 3505
email ashin@iu.edu 
Journal name: Patient Preference and Adherence
Article Designation: Review
Year: 2016
Volume: 10
Running head verso: Shin
Running head recto: Prucalopride in chronic constipation
DOI: http://dx.doi.org/10.2147/PPA.S92550
Patient Preference and Adherence 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1374
Shin
33.5% among the elderly.4 Prevalence of constipation may 
also vary based on sex and race, with a higher prevalence 
being reported among females5,6 and in nonwhite populations 
compared with white populations.1
The economic burden and psychosocial impact of con-
stipation are significant. Constipation is associated with 
productivity losses, increased health care utilization, and 
impairment in quality of life (QOL).7,8 In a web-based survey 
conducted in the US of 557 participants, symptoms of consti-
pation affected QOL in .50% of respondents and decreased 
work productivity with a mean absence of 2.4 days in 12% 
of respondents who worked or attended school.9 A separate 
survey conducted in Canada showed that among patients with 
self-reported constipation or functional constipation based 
on Rome II criteria, physical and mental components of the 
Short Form 36 were found to be significantly lower compared 
with Canadian norms and poorer QOL was observed to be a 
strong predictor of health care utilization.10
Estimated ambulatory visits for constipation in the US 
have risen dramatically over the last several decades, with 
recent reports estimating 8 million visits annually from 
2001 to 2004, constituting 33.4% of visits with primary care 
providers and 14.1% of visits with gastroenterologists.11 
The majority of physician visits for constipation result in 
a prescription for a laxative, and it has been estimated that 
Americans spend $800 million per year on such treatments.12 
Despite the frequent use of laxatives, fiber, and other pre-
scription medications, up to 50% of patients report they 
are not completely satisfied with their current treatment for 
constipation.9 Furthermore, the frequency of constipation-
related emergency department visits increased by 41.5% 
from 2006 to 2011, and the aggregate national cost of 
constipation-related emergency department visits increased 
by 121.4% from 723,886,977 in 2006 to .1.6 billion in 2011 
after adjustment for inflation,13 emphasizing the need for 
improved diagnosis and management of chronic constipation 
in the outpatient setting.
Pathophysiology of chronic 
constipation
Symptoms of constipation may be related to various under-
lying mechanisms, including abnormal colonic transit and 
defecatory disorders, which may occur in the context of 
slow colonic transit.14 Thus, careful consideration of the 
pathophysiology of chronic constipation remains impor-
tant in providing targeted strategies for management and 
treatment.1 For example, first-line intervention for rectal 
evacuation disorders may include biofeedback-aided pelvic 
floor therapy, which has previously been demonstrated as 
effective and may even result in improved colonic transit.15–18 
Slow colonic transit may also occur in isolation and delayed 
transit may serve as a surrogate marker for impaired colonic 
motility.19,20 The spectrum of patients may include those 
with colonic inertia, characterized by marked impairment in 
contractile responses to a meal or pharmacological stimulus. 
Even among patients with “normal” colonic transit, there is 
evidence supporting the presence of underlying colonic motor 
dysfunction, as reflected by reduction in colonic tone.19
Current pharmacological agents for 
the treatment of constipation
Initial steps in pharmacological management21 of constipa-
tion (Figure 1) generally begin with fiber supplementation 
or bulking agents followed by the use of osmotic laxatives, 
which may include polyethylene glycol (PEG)-based laxa-
tives, magnesium salts, and poorly absorbed carbohydrates 
(eg, sorbitol and lactulose). For those with a suboptimal 
response to osmotic laxatives, stimulant laxatives, includ-
ing bisacodyl or senna, may be effective as a supplementary 
agent. The majority of these agents are available over-the-
counter without a prescription and are relatively inexpensive. 
Newer pharmacological agents currently approved for the 
treatment of chronic constipation include intestinal secret-
agogues, such as lubiprostone and linaclotide, for those who 
have failed first-line therapies. However, newer agents can be 
relatively expensive and are available by prescription only. 
Both lubiprostone and linaclotide facilitate intestinal chloride 
secretion; lubiprostone via activation of apical type 2 chloride 
channels and linaclotide via activation of guanylyl cyclase C. 
Prokinetic agents targeting 5-hydroxytryptamine receptor-4 
(5-HT
4
) and motilin receptors have also been considered as 
a therapeutic approach for constipation, although most are 
not easily available in the US or are undergoing ongoing 
investigation.22 A recent review summarizing the cost of 
treatment for constipation reported estimated monthly costs 
ranging from $0.34 per month for senna to $293.02 for lubi-
prostone. Meanwhile, over-the-counter bulking agents such 
as psyllium and laxatives such as PEG 3350 were estimated 
to cost $14.22 and $18.25 per month, respectively.23
5-HT4 agonists for the treatment 
of chronic constipation
5-HT
4
 receptors are members of the G-protein-coupled family 
of receptors widely expressed throughout the gastrointestinal 
tract on enteric neurons24 and smooth muscle cells25 and have 
been extensively studied as targets for prokinetic treatment. 
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Activation of these receptors promotes mucosal secretion 
and gastrointestinal motility26 through enhanced cholinergic 
transmission and relaxation of inhibitory circular smooth 
muscle.27
Several classes of 5-HT
4
 agonists have been developed 
as prokinetic agents for the treatment of gastrointestinal 
disorders, and different agents exhibit differing levels of 
affinity and selectivity for the 5-HT
4
 receptor. Early 5-HT
4
 
receptor agonists, including cisapride and tegaserod, were 
previously withdrawn from the market due to the association 
with adverse QT prolongation and cardiovascular side effects 
resulting from their lack of selectivity for 5-HT
4
 receptors and 
affinity for the human ether-à-go-go-related gene (hERG)-
encoding potassium channel28 and 5-HT
1
 or 5-HT
2
 receptors 
unrelated to 5-HT
4
 receptor agonism.24
Unlike tegaserod and cisapride, newer highly selec-
tive 5-HT
4
 receptor agonists, including prucalopride,24 
velusetrag,29 and naronapride (ATI-7505),30 do not display 
affinity for hERG channels nor 5-HT receptor subtypes asso-
ciated with the previously reported arrhythmias and adverse 
cardiovascular effects. In fact, cardiac safety of prucalopride 
has been assessed in healthy volunteers through a prospective 
double-blind, placebo-, and active-controlled study, in which 
volunteers were randomized to therapeutic and suprathera-
peutic doses of prucalopride or placebo with moxifloxacin to 
show no clinically significant effects on corrected QT interval 
(QTc).31 A recent systematic review evaluating highly selec-
tive 5-HT
4
 receptor agonists on patient-important clinical 
efficacy outcomes and safety demonstrated that relative to 
control, treatments with highly selective 5-HT
4
 agonists 
were superior in improving bowel function, symptoms, and 
QOL while maintaining a favorable safety profile.32 Despite 
their potential, none of the newer 5-HT
4
 agonists have been 
approved by the FDA for the treatment of constipation in the 
US, and there remains misperception and confusion regarding 
their safety profile, even among experienced clinicians.
Focus on prucalopride
Of the different 5-HT
4
 agonists that have been developed, evi-
dence for clinical efficacy is most available for prucalopride. 
Prucalopride is a first-in-class dihydrobenzofuran carboxam-
ide derivative that is highly selective for the 5-HT
4
 receptor 
with potent enterokinetic properties.33 Prucalopride has been 
approved by the European Medicine Agency for the treatment 
of chronic constipation in adults in whom laxative therapy 
has failed34 and is now approved in several countries for the 
treatment of chronic constipation at doses of 2 mg/d for adults 
and 1 mg/d for elderly patients.35
Preclinical pharmacological and 
pharmacodynamic studies on 
prucalopride
Studies on the pharmacological profile of prucalopride dem-
onstrating its prokinetic effects and high selectivity for the 
5-HT
4
 receptor have been performed in several preclinical 
animal models. Prucalopride exhibits a high affinity only 
for the 5-HT
4b
 and 5-HT
4a
 receptors (Ki value of 8 nM and 
2.5 nM, respectively) and at least a 290-fold selectivity 
for the 5-HT
4
 receptor. It has been shown to be devoid of 
undesirable anticholinergic and anticholinesterase activity.36 
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Figure 1 Algorithm for management of chronic constipation.
Note: *Approved by the european Medicine Agency, not FDA approved in the US.
Abbreviation: FDA, Food and Drug Administration.
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Observations have been further supported in vivo in fasted 
dogs where prucalopride administration caused stimulation 
of high-amplitude clustered contractions in the proximal 
colon and inhibition of distal contractile activity in a 
dose-dependent fashion. Contractile motility patterns were 
completely inhibited with administration of a 5-HT
4
 receptor 
agonist,37 suggesting the effects of prucalopride to be specifi-
cally mediated via 5-HT
4
 receptors.
Consistent with preclinical pharmacological studies, data 
from placebo-controlled studies (ie, studies utilizing inert 
substances without known activity as the control treatment)38 
performed among healthy volunteers have shown prokinetic 
properties of prucalopride and effects on stool frequency 
and consistency in humans. Efficacy of prucalopride was 
shown in a placebo-controlled study performed in 50 healthy 
volunteers, in which treatment with prucalopride daily was 
associated with acceleration of overall colonic transit with 
no significant effects on gastric emptying or small bowel 
transit.39 In a separate double-blind, placebo-controlled, 
crossover study by Poen et al,40 treatment with 2 mg of 
prucalopride daily was associated with an increase in mean 
colonic transit time and significant increases in weekly stool 
frequency and percentage of loose or watery stools. Find-
ings of increased gastrointestinal transit, increased stool 
frequency, and decreased stool consistency were also noted 
in a similarly designed trial by Emmanuel et al.41
Phase II trials in patients with 
chronic constipation
In patients with chronic constipation, data supporting the 
safety and efficacy of prucalopride have been shown in 
several Phase II clinical trials. In a double-blind Phase 
II trial among females with constipation, treatment with 
1 mg of prucalopride daily for 4 weeks was associated with 
acceleration of whole gut transit compared with placebo, 
and subgroup analysis further revealed this effect to be 
limited to patients with slow transit. Treatment with pruca-
lopride was also associated with a significant improvement 
in symptoms, shorter time to first bowel movement, and 
alterations in rectal sensitivity.42 In male and female patients 
with functional constipation, treatment with 1 mg or 2 mg of 
prucalopride resulted in a numerical improvement in mean 
colonic transit time compared with placebo, although results 
were not statistically significant. Treatment with the 1 mg 
dose was associated with significant increases in spontane-
ous complete bowel movement (SCBM) frequency while no 
differences in anorectal function were seen between treat-
ment groups.43 Effects of 2 mg or 4 mg of prucalopride on 
gastrointestinal and colonic transit were also assessed using 
validated scintigraphy by investigators in 40 patients (four 
males and 36 females) with functional constipation without 
evidence of a rectal evacuation disorder. In contrast to their 
prior study among healthy volunteers,39 significant accel-
eration of overall gastric emptying and small bowel transit 
time was observed. The 4 mg treatment dose was associated 
with significant acceleration of overall colonic transit at 
24 hours, but observed differences for the overall treatment 
group vs placebo were of borderline significance (P=0.1).44 
In patients with severe constipation referred to a tertiary care 
center, treatment with 4 mg of prucalopride was found to 
significantly improve stool consistency and time to first stool. 
Positive effects on stool frequency and whole gut transit were 
observed, although these observations were not statistically 
significant.45 Taken together, studies on patients with chronic 
constipation suggested positive effects of prucalopride on 
gastrointestinal transit and bowel functions. However, these 
data remained somewhat inconclusive given the lack of sig-
nificant differences seen in individual studies.
Hence, to better characterize the effects of prucalopride 
on colonic transit, and the relationship between transit and 
symptoms, an integrated analysis was recently performed 
combining the results of three Phase II placebo-controlled 
trials in patients with chronic constipation assessing the 
effects of prucalopride on transit and the relationship between 
transit and symptoms.46 A total of 280 patients were included 
in the analysis, 70% of whom had slow or very slow colonic 
transit at baseline. The results showed that treatment with 
prucalopride was associated with significant decreases in 
mean colonic transit compared with baseline for both the 
2 mg (12.0 hours, P,0.001) and 4 mg (13.9 hours, P,0.001) 
doses, while no significant changes were observed in the 
placebo group. In addition, a relationship was observed 
between symptom severity and colonic transit with a higher 
proportion of patients with slow or very slow colonic tran-
sit reporting constipation symptoms as “severe” or “very 
severe”. Increased stool consistency was found to be cor-
related with increased colonic transit. The results of this 
analysis indicated improvement in colonic transit and stool 
consistency with prucalopride and suggested improved 
colonic transit as a contributing mechanism for reduction in 
constipation symptoms.
Pivotal Phase III trials
To date, there have been five large multicenter Phase III 
trials of prucalopride that have demonstrated improvement in 
bowel function, overall symptom scores, patient satisfaction, 
and QOL scores in patients with chronic constipation. All 
trials were of similar design, involving a 12-week treatment 
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duration in which eligible participants were randomized to 
prucalopride or placebo after a 2–4-week run-in phase. Three 
pivotal trials47–49 were performed in predominantly Caucasian 
patients using either 2 mg or 4 mg of prucalopride. A fourth 
trial was later performed in a predominantly Asian population 
using 2 mg once daily.50 In these four trials, it was noted that 
only 10% were males and more recently, a fifth multicenter 
Phase III trial was published evaluating the efficacy and 
safety of prucalopride for the treatment of chronic constipa-
tion among males.51 In the three initial Phase III trials,47–49 
significantly more patients randomized to prucalopride 
achieved the primary efficacy end point (ranging from 20% 
to 30% for prucalopride vs 9% to 12% for placebo) of three 
or more SCBMs per week as well as increases of one or more 
SCBMs per week from baseline compared with placebo. 
Treatment effects were seen for both doses of prucalopride, 
and analysis of secondary end points also showed that 
patients treated with prucalopride achieved greater satis-
faction with treatment, bowel function, and an improved 
perception of constipation-related QOL. Completion of the 
three pivotal trials was followed by an open-label study52 in 
which patients who completed the initial Phase III studies 
were invited to continue treatment in two studies of similar 
design (PRU-INT-10 and PRU-USA-22) to assess long-term 
satisfaction with bowel function for treatment durations of 
up to 24 and 36 months. Of those participating in the blinded 
Phase III trials, 86% elected to proceed with the open-label 
study with at least 12 months of study data available for the 
majority (54%) of patients and a total calculated exposure 
to prucalopride of 1,464 patient-years at study completion. 
Assessment of patient satisfaction using the Patient Assess-
ment of Constipation-QOL (PAC-QOL) scale showed that 
the improvement achieved in the double-blind studies with 
prucalopride treatment was maintained for up to 18 months 
and a similar improvement was seen in the first 3 months of 
the open-label study for patients who received placebo during 
the double-blind trials. Between 43% and 67% of patients 
achieved $1 point improvement in their satisfaction over the 
18-month period. In total, 8% of patients discontinued the 
open-label study secondary to adverse events (AEs), with 
the most commonly reported AEs being abdominal pain, 
diarrhea, headache, and nausea.
Clinical efficacy in special 
population
Müller-Lissner et al demonstrated the beneficial effects of pru-
calopride on bowel function, symptoms, and QOL in a 4-week 
randomized placebo-controlled trial in patients $65 years of 
age with chronic constipation. The effect of prucalopride on 
bowel movements was greatest after the first week of treat-
ment. Safety assessments revealed a slightly higher incidence 
of abdominal pain, diarrhea, and headache in the treatment 
group consistent with larger Phase III trials. However, all 
AEs were considered to be only mild or moderate in severity, 
and no clinically relevant findings were noted with respect to 
cardiovascular safety or electrocardiography (ECG) variables 
including QTc intervals.53
Ke et al50 published the results of a large randomized 
placebo-controlled Phase III trial of prucalopride in patients 
with chronic constipation from the Asia-Pacific region. Part 
of the rationale for this study was the recognized potential 
for altered pharmacokinetic and pharmacodynamic drug pro-
files based on race and ethnicity. Investigators demonstrated 
the efficacy of prucalopride among Asians with significant 
improvements in bowel function, bowel symptoms, patient 
satisfaction, and QOL. Analysis of the primary efficacy end 
point showed that 33.3% prucalopride-treated patients vs 
10.3% placebo-treated patients achieved a weekly average of 
at least three SCBMs per week over the 12-week treatment 
course, whereas 57% prucalopride-treated patients vs 27% 
placebo-treated patients experienced an average increase of 
one or more SCBMs per week from baseline. Significant 
improvements were also observed in overall QOL scores 
and all subscales (dissatisfaction, physical discomfort, psy-
chosocial discomfort, and worries and concerns). Frequently 
reported AEs were diarrhea, abdominal pain, nausea, and 
headache, similar to prior Phase III trials among Caucasians 
with no unexpected safety findings observed.
Finally, recent data published from a multicenter trial in 
males with chronic constipation reported prucalopride to be 
significantly more effective in improvement of bowel func-
tion vs placebo, with 38% of prucalopride-treated patients 
achieving the primary end point vs 17.7% of placebo-treated 
patients. The proportion of patients (47% prucalopride vs 
30.4% placebo, P,0.0001) rating treatment as effective and 
the proportion of patients (53% prucalopride vs 39% placebo, 
P=0.0035) reporting at least a 1 point improvement in the 
PAC-QOL satisfaction scores were significantly increased 
in the prucalopride group.51
Comparison of prucalopride with 
available treatment options
To date, there has been only one randomized controlled trial 
of prucalopride using an active comparator, PEG 3350+E, 
an established osmotic laxative that is widely available for 
the treatment of constipation in both adults and children.54 
PEG 3350+E has a significantly lower cost for 14 days of 
treatment compared with prucalopride,55 and in this Phase III 
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clinical trial, investigators demonstrated noninferiority of 
PEG 3350+E vs prucalopride for the primary end point of 
the proportion of patients achieving $3 SCBMs during the 
last week of treatment. Results of patient assessments and 
QOL also showed that more patients randomized to PEG 
3350+E rated treatment as “very” or “extremely effective”, 
while stool symptom, rectal symptoms, and global assess-
ment scores also improved more with PEG 3350+E than with 
prucalopride. Conversely, abdominal symptoms were more 
improved with prucalopride after the first 7 days. Given the 
findings of this study, the authors argue that PEG 3350+E 
remains the more cost-effective treatment and should be the 
first-line approach for the treatment of chronic constipa-
tion. However, the long-term durability of these findings 
will require further scrutiny, as this study was limited to a 
4-week duration due to its design in which participants were 
assessed in a controlled Phase I unit to allow for control 
of environmental factors and ensure accuracy of outcome 
assessments.
Currently underway is a prospective randomized mul-
ticenter trial aiming to compare the efficacy of electroa-
cupuncture, a commonly used complementary/alternative 
therapy for the treatment of chronic constipation, with that 
of prucalopride in patients with constipation. The objectives 
of this Phase II study are to assess the primary outcome of 
the proportion of patients achieving three or more SCBMs 
per week as well as secondary outcomes of $1 increase in 
SCBMs per week from baseline, changes in SCBMs per week 
from baseline, stool consistency, and PAC-QOL.56
Patient perspectives with focus on 
important outcomes of patients
In order to evaluate the impact of treatment on patients with 
chronic constipation, all clinically relevant important out-
comes of patients should be considered in efficacy analyses in 
clinical trials of prucalopride and other investigational agents. 
The impact of chronic constipation on health-related QOL 
is significant and has been reported to be comparable with 
conditions such as allergies, musculoskeletal impairments, 
and inflammatory bowel disease.8 Hence, the inclusion of 
multiple efficacy outcomes including stool frequency, stool 
consistency, symptoms, global patient satisfaction, and 
health-related QOL has been critical in allowing for a more 
comprehensive assessment of patient responses and percep-
tions. In clinical practice, focus on patient-reported symptoms 
is particularly important as individual bowel habits may vary 
and the definition of constipation may be interpreted differ-
ently by both the patient and the physician.57
All aforementioned Phase III clinical trials of 
prucalopride47–49 and follow-up open-label study52 have incor-
porated patient-reported outcomes of symptoms, satisfaction, 
and QOL. The Patient Assessment of Constipation-Symptoms 
(PAC-SYM) is a validated questionnaire addressing 
12 constipation-related symptoms scored on three subscales: 
stool, abdominal, or rectal symptoms for which an overall 
score and a score for each subscale can be determined to 
address patient perspectives on chronic constipation.58 This 
questionnaire has been shown to be internally consistent, 
responsive to change, and able to differentiate between 
groups of patients based on clinical severity of constipation. 
More recently, the psychometric properties of this instrument 
were investigated in .2,000 outpatients with chronic consti-
pation. The relevance of the rectal domain was questioned 
as only 38% of patients reported symptoms of rectal tearing 
and thus a modified eleven-item PAC-SYM was developed 
to demonstrate reliability as well as correlation with health-
related QOL and treatment satisfication,59 supporting its use 
as a measure of symptom severity in patients seeking care for 
treatment of chronic constipation. An integrated analysis60 
combining data from the three pivotal Phase III trials47–49 to 
evaluate the effects of prucalopride on constipation symp-
toms as measured by the PAC-SYM questionnaire showed 
prucalopride to have a large effect on common symptoms of 
constipation as assessed by the PAC-SYM (Figure 2).60 The 
largest improvements in subscale scores were observed for 
abdominal symptoms and stool symptom scores, whereas 
smaller improvements were observed for the rectal symp-
toms score.
Assessment of patient satisfaction and health-related QOL 
has been measured using the previously validated PAC-QOL 
questionnaire, a 28-item instrument consisting of an overall 
scale and four separate subscales: 1) physical discomfort; 
2) psychosocial discomfort; 3) worries and concerns; and 4) 
patient satisfaction.61 Validity, reliability, and responsiveness 
of this instrument have been demonstrated in multinational 
studies to establish its utility as a comprehensive assessment 
of patients’ well-being.62
Due to uncertainty regarding the clinical significance of 
PAC-QOL scores and the clinical relevance of detecting a 
1 point improvement in scores in the three pivotal Phase III 
trials, investigators conducted a pooled analysis to assess 
psychometric properties of the PAC-QOL and provide 
guidance for interpretation.61 Results showed the psycho-
metric properties of the PAC-QOL among patients in the 
prucalopride trials to be internally consistent, reliable, and 
responsive. A significant relationship was observed between 
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PAC-QOL scores and severity of constipation as measured 
by PAC-SYM and stool frequency, demonstrating the 
importance of stool frequency in the patients’ perception of 
constipation. Calculation of the minimum important differ-
ence using distribution- and anchor-based methods was ,0.5 
and ,0.9, respectively, indicating a 1 point difference to be 
clinically relevant. Meanwhile, the majority of patients with 
at least a 1 point improvement in PAC-QOL scores showed 
consistent improvements in treatment efficacy and symptom 
severity. Results of this analysis served to further support 
the use of the PAC-QOL as an important assessment tool in 
measuring patient perspectives in response to treatment in 
both a clinical and research setting.
Recognizing the importance of patient-reported outcomes 
and tools such as the PAC-QOL, Tack et al63 performed an 
integrated analysis using data from the three pivotal Phase III 
trials to further investigate the relationship between health-
related QOL as assessed by the PAC-QOL and symptom 
severity. Analysis of the relationship between PAC-QOL 
and PAC-SYM using data from the intention-to-treat popu-
lation showed that for both the PAC-SYM and PAC-QOL, 
significantly more patients in the 2 mg prucalopride group 
achieved $1 point improvement in the total score after 
12 weeks compared with placebo. Among patients achiev-
ing $1 point improvement in overall PAC-QOL score, 66% 
also had a $1 point improvement in overall PAC-SYM with 
a strong linear positive correlation for change in baseline 
to week 12 between overall PAC-SYM and PAC-QOL 
scores (r=0.711). Among patients who achieved the primary 
efficacy end point of three or more SCBMs per week over 
12 weeks of treatment, 72.4% achieved an improvement 
of $1 point on the PAC-QOL satisfaction score (Figure 3).63 
Results demonstrated the correlation between health-related 
QOL and improvement in stool frequency and symptoms in 
patients with chronic constipation.
Safety and AEs
Documentation of safety and tolerability of highly selective 
5-HT
4
 agonists such as prucalopride remains a critically 
important component in assessment of patient outcomes 
and responses. In all five Phase III clinical trials of pruca-
lopride, careful safety assessments have been incorporated 
to document AEs and tolerability, with particular emphasis 
on cardiovascular risks and ECG parameters. Total number 
of AEs and discontinuation rates from all five Phase III 
trials are summarized in Table 1. In general, the most com-
monly reported AEs include headache, diarrhea, nausea, 
and abdominal pain (Table 2) with no major cardiovascular 
safety concerns being observed. In the multicenter trial 
performed in the US by Camilleri et al,47 AEs were reported 
at weeks 2, 4, 8, and 12 of treatment, and results of ECG, 
clinical laboratory tests, and physician examinations were 
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Figure 2 effect of prucalopride on symptoms of chronic constipation as assessed by the Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM). PAC-SYM 
effect sizes at week 12 in women in whom laxatives had failed to provide adequate relief – an integrated analysis of three identical double-blind phase iii trials.
Note: Reproduced from Tack J, Stanghellini v, Dubois D, Joseph A, vandeplassche L, Kerstens R. effect of prucalopride on symptoms of chronic constipa tion. © 2013 The 
Authors. Neurogastroenterology & Motility published by John wiley & Sons Ltd.60
Abbreviations: BM, bowel movement; PRU, prucalopride.
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evaluated at screening and at weeks 4 and 12. Most AEs 
were mild or moderate, and serious AEs were reported 
in 3.4% of patients receiving 4 mg of prucalopride, 1.4% 
of patients receiving 2 mg of prucalopride, and 3.8% of 
patients receiving placebo. The incidence of AEs was 
similar in all three treatment groups with the exception of 
diarrhea and headache, which were more frequently reported 
with prucalopride. Importantly, there were no significant 
differences in incidence of prolonged QTc between groups 
and no clinically significant cardiac events occurred with 
the exception of one patient with a preexisting history of 
mitral valve prolapse and supraventricular tachycardia in 
whom that condition occurred while receiving treatment 
with prucalopride.
Safety assessments were conducted in a similar fash-
ion in a separate multicenter Phase III trial throughout 41 
centers in the US by Quigley et al.48 The most frequently 
reported AEs again included headache, nausea, abdominal 
pain, diarrhea, and flatulence, and these were more common 
among patients in the prucalopride group on the first day of 
treatment. However, when excluding the first treatment day, 
incidence of AEs was similar across groups. Severe AEs were 
reported in 15% of patients treated with 2 mg of prucalopride, 
21% of patients treated with 4 mg of prucalopride, and 10% 
of patients treated with placebo. Most severe AEs involved 
the gastrointestinal system and a higher incidence of severe 
headache was observed in the prucalopride groups. Inci-
dence of serious AEs did not differ by the treatment group. 
The incidence of prolonged QTc was low overall, with no 
significant difference between groups.
In the third pivotal trial by Tack et al,49 safety assess-
ments demonstrated that most AEs were mild or moderate, 
and transient. Increased AEs in the prucalopride group were 
noted mainly on day 1 but were otherwise similar between 
groups. The most common AEs were headache, nausea, 
abdominal pain, and diarrhea, as noted in the other Phase III 
trials of similar size and design. Interestingly, severe diar-
rhea was not higher with prucalopride. Discontinuation 
secondary to AEs was highest in the group assigned to 4 mg 
of prucalopride. Consistent with prior reports, no clinically 
significant differences in ECG parameters or incidence of 
QTc prolongation were observed between groups.
Safety assessments in the Phase III trial conducted 
among patients from the Asia-Pacific region50 showed that 
Improvement in PAC-QOL satisfaction score
≥1 point <1 point
Mean number of SCBMs/week
≥3 SCBMs/week <3 SCBMs/week
All patients Patients with
≥1 point improvement in
PAC-QOL satisfaction score
All patients
Patients with
≥3 SCBMs/week
33.3%
n=423
66.7%
n=847
61.0%
n=258
82.0%
n=1,042
27.6%
n=63
72.4%
n=165
18.0%
n=228
39.0%
n=165
A
B
Figure 3 Association between Patient Assessment of Constipation-Quality of Life 
(PAC-QOL) satisfaction score and primary efficacy end point of three or more 
spontaneous complete bowel movements (SCBMs) per week over 12 weeks in 
three pivotal Phase iii clinical trials.
Notes: Reproduced from Tack J, Camilleri M, Dubois D, vandeplassche L, Joseph A, 
Kerstens R. Association between health-related quality of life and symptoms in 
patients with chronic constipation: an integrated analysis of three phase 3 trials of 
prucalopride. © 2015 The Authors. Neurogastroenterology & Motility published 
by John wiley & Sons Ltd.63 (A) The proportion of patients who achieved $3 
or ,3 SCBMs/week as a subset of patients how achieved $1 point improvement 
in satisfaction. (B) The proportion with an improvement in satisfaction of $1 
or ,1 point as a subset of patients who achieved a mean of $3 SCBMs/week. 
Combined data for all patients in the combined intent-to-treat population from the 
Phase 3 trials, treated with placebo or prucalopride 2 mg.
Table 1 Summary of TeAes and rates of discontinuation in Phase iii clinical trials of PRU
Study PRU patients 
with $1 TEAEs 
(2 mg, 4 mg; %)
PCBO patients 
with $1 TEAEs 
(%)
Discontinuation of treatment 
due to AEs among PRU 
patients (2 mg, 4 mg; %)
Discontinuation of treatment 
due to AEs among PCBO 
patients (%)
Camilleri et al20 80.2, 78.4 71.3 8.2, 7.8 1.9
Quigley et al48 81.0, 76.0 66.0 4.0, 6.0 2.0
Tack et al49 71.4, 74.8 67.1 6.3, 15.1 6.7
Ke et al50 57.0, NA 36.5 3.2, NA 1.2
Yiannakou et al51 42.4, NA 34.4 3.3, NA 3.8
Abbreviations: TeAes, treatment-emergent adverse events; PRU, prucalopride; PCBO, placebo; Aes, adverse events; NA, not applicable.
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the total proportion of patients experiencing at least one 
AE was higher in the prucalopride-treated group than in 
the placebo-treated group. Serious AEs occurred in 1.2% 
of patients treated with prucalopride and 2.0% of patients 
treated with placebo, while AEs leading to discontinuation 
of study drug occurred in 3.2% of patients treated with 
prucalopride and 1.2% of patients treated with placebo. The 
most commonly reported AEs included diarrhea, headache, 
nausea, and abdominal pain, and all occurred more fre-
quently in the prucalopride-treated group. The incidence 
of treatment-emergent cardiovascular events, including 
palpitations, cardiovascular ischemic events, arrhythmias, 
and QT prolongation, was low overall and similar between 
treatment groups. In the prucalopride group, there was one 
patient with ECG signs of myocardial ischemia. Abnormal 
values in ECG parameters, including QT interval, were not 
observed in patients with normal baseline values after treat-
ment with prucalopride.
In the most recently published Phase III trial among 
males with chronic constipation,51 a total of 42.4% of 
prucalopride-treated patients and 34.4% of placebo-treated 
patients experienced at least one treatment-emergent AE 
(TEAE), although the difference was not significant. The 
most commonly reported TEAEs associated with prucalo-
pride were diarrhea, nausea, abdominal pain, and headache. 
Most TEAEs were mild or moderate, and serious TEAEs 
were reported in one patient in the prucalopride group and 
four patients in the placebo group. Treatment discontinua-
tion secondary to AEs was similar between groups (3.3% 
with prucalopride vs 3.8% with placebo). Overall incidence 
of cardiovascular AEs was low (two patients in the placebo 
group with angina and myocardial ischemia and one patient 
in the prucalopride group with coronary artery occlusion). 
There was one patient with QT prolongation at week 4 in 
the prucalopride group; however, values returned to normal 
at week 12 and study treatment continued.
Safety and tolerability of prucalopride have also been 
evaluated in elderly patients with chronic constipation 
residing at nursing homes in a Phase II dose-escalation study 
for up to 4 weeks of treatment, which included rigorous safety 
assessments comprising documentation of patient-reported 
AEs, pharmacokinetic assessments, serial laboratory tests, 
evaluation with serial ECGs, and continuous Holter monitor-
ing per study protocol.64 It should be noted that 88% of the 
study population had a history of relevant cardiovascular 
disease. Overall, AEs were reported in 50% of patients treated 
with placebo, 85.7% of patients treated with 0.5 mg of pruca-
lopride, 70.8% of patients treated with 1 mg of prucalopride, 
and 69.2% of patients treated with 2 mg of prucalopride. The 
most commonly reported AEs included diarrhea, abdominal 
pain, and headache. Diarrhea and headache were more com-
monly reported in the prucalopride groups and abdominal 
pain was more commonly reported in the placebo group. 
Most AEs were mild or moderate in severity. Evaluation of 
cardiovascular parameters revealed no clinically significant 
differences in change in heart rate or ECG parameters (PR, 
QT, QTcB, or QTcF intervals) between groups. Increase in 
QTc interval from baseline resulting in a prolonged QTc 
of 473 ms was observed in one female patient with a his-
tory of a pacemaker and extensive cardiovascular disease. 
Holter monitoring did not reveal any significant differences 
in the incidence of arrhythmic or supraventricular events 
between groups. Findings suggested prucalopride to be safe 
and well tolerated even among elderly patients with chronic 
constipation.
Factors associated with the occurrence of TEAEs have 
been further assessed in a recent integrated analysis to 
show a higher prevalence of diarrhea, headache, and nausea 
with prucalopride compared with placebo. Interestingly, 
it was noted that diarrhea occurred at a higher frequency 
among Asians, while headache, abdominal pain, and nau-
sea occurred at a lower frequency among Asians compared 
with non-Asians.35 In summary, the evidence from multiple 
clinical trials and follow-up analyses using pooled data has 
repeatedly demonstrated the relative safety of prucalopride 
for the treatment of chronic constipation.
Table 2 Frequency of most commonly reported Aes in Phase iii clinical trials of PRU
Study Diarrhea PRU 
(2 mg, 4 mg; %)
Diarrhea 
PCBO (%)
Abd pain PRU 
(2 mg, 4 mg; %)
Abd pain 
PCBO (%)
Nausea PRU 
(2 mg, 4 mg; %)
Nausea 
PCBO
Headache PRU 
(2 mg, 4 mg; %)
Headache 
PCBO (%)
Camilleri et al20 13.5, 18.6 5.3 19.3, 22.5 19.1 22.2, 21.6 8.1 26.6, 29.4 12.0
Quigley et al48 11.0, 13.0 4.0 18.0, 16.5 10.0 12.0, 21.0 8.0 25.0, 25.0 15.0
Tack et al49 13.0, 12.6 5.4 23.1, 18.5 17.1 23.9, 23.5 14.2 26.1, 29.8 16.7
Ke et al50 22.1, NA 7.9 6.8, NA 2.4 11.6, NA 3.2 12.4, NA 2.0
Yiannakou et al51 6.5, NA 1.6 4.3, NA 5.9 6.0, NA 2.2 9.2, NA 3.8
Abbreviations: Aes, adverse events; PRU, prucalopride; PCBO, placebo; Abd, abdominal; NA, not applicable.
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Postmarketing surveillance (results 
of a Phase IV clinical trial)
Given the promising results from the initial Phase III studies 
of prucalopride in patients with chronic constipation as well 
as the results of the open-label follow-up study, a Phase IV 
clinical trial investigating long-term efficacy and safety 
was recently undertaken at 50 sites across Europe.65 In this 
trial, adults with chronic constipation were randomized to 
24 weeks of treatment with either placebo or prucalopride. 
The primary efficacy end point was the proportion of patients 
achieving an average of three or more SCBMs per week 
over the 24-week treatment duration. Secondary end points 
focused on safety, tolerability, and effects on health-related 
QOL. A total of 182 patients were recruited and enrolled in 
each treatment arm, with 126 patients in the placebo group 
and 135 patients in the prucalopride group completing the 
study. The primary efficacy end point was achieved by 
25.1% in the prucalopride group and 20.7% in the placebo 
group using the intention-to-treat population with no sta-
tistically significant difference between groups. Analysis 
of the first 12 weeks as well as sensitivity analyses using 
the perprotocol and completer populations showed similar 
findings. However, an additional sensitivity analysis using 
a generalized linear model showed a significant difference 
with a greater proportion of responders in the prucalopride 
group compared with placebo over 12 and 24 weeks. Inter-
estingly, analysis of secondary end points revealed the 
proportion of patients reporting a $1 point improvement 
in the PAC-SYM score to be significantly greater in the 
placebo group than in the prucalopride group, whereas the 
proportion of patients with an improvement in PAC-QOL 
did not significantly differ between groups. Results of safety 
assessments were similar to those in previously published 
trials. No significant differences were observed between 
groups with respect to total proportion of patients experi-
encing at least one TEAE or serious AEs, and no clinically 
significant changes were observed in QT prolongation or 
ECG parameters throughout the study duration. The most 
commonly reported AEs included headache, abdominal pain, 
and nausea. The authors were unable to explain the lack 
of efficacy of prucalopride in this long-term trial, despite 
the use of several sensitivity analyses. However, further 
consideration may be given to the larger than previously 
observed placebo response rate as well as the possible impact 
of patient selection without careful exclusion of patients 
with an underlying rectal evacuation disorder. When com-
bined with data from prior Phase III trials in an integrated 
analysis, results continue to demonstrate global efficacy and 
a favorable safety profile of prucalopride for the treatment 
of chronic constipation.66
Conclusion
Chronic constipation remains a common and an important 
clinical condition with a substantial impact on health care 
utilization and health-related QOL. Newer agents now avail-
able for treatment include the highly selective 5-HT
4
 receptor 
agonist, prucalopride. Efficacy and safety of prucalopride 
have been demonstrated in multiple randomized clinical 
trials, and special emphasis has been placed on examining 
potential cardiovascular risks to show prucalopride to be 
a safe treatment option for patients with chronic constipa-
tion, including special populations such as elderly patients. 
Clinical trial data have also provided evidence to support its 
efficacy through assessment of constipation symptoms and 
health-related QOL scores, which serve to reflect patient-
important outcome measures beyond that of stool frequency 
and bowel function.
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